Microbot Medical adds Sanmina manufacturing capacity for LIBERTY
Microbot Medical signed a letter of agreement with Sanmina to manufacture the FDA-cleared LIBERTY Endovascular Robotic System.
Evidence notes
- Microbot framed the agreement as a second manufacturing site and capacity expansion.
- The company linked the expansion to demand from existing and new accounts.
Company context
Microbot Medical develops LIBERTY, a compact single-use endovascular robotic system designed for remotely operated vascular access and navigation.